25th Annual PPAG Conference Schedule and Learning Objectives
Atlanta Marriott Marquis | April 27- May 1, 2016
Atlanta, Georgia

Looking for Handouts?
Go to:
https://www.ppag.org/?pg=25AM_Handouts​

 

Wednesday, April 27, 2016 | NICU Sessions

Welcome
10:00:00 AM - 10:10:00 AM
Marquis Ballroom B

Jared Cash, PharmD- President of PPAG
Director of Pharmacy
Primary Children’s Hospital
Salt Lake City, Utah


2016 Neonatal Candidiasis Guideline Review
0180-0000-16-200-L01-P
10:10:00 AM - 10:30:00 AM
Marquis Ballroom B

Miranda Nelson, PharmD
Antimicrobial Stewardship Pharmacist
St. Louis Children's Hospital
St. Louis, Missouri

At the end of this session, participants will be able to:

1.       Review the current recommendations for the treatment of neonatal candidiasis

2.      Evaluate the literature utilized in the development of the neonatal candidiasis guideline recommendations

3.      Identify the situations in which anti-fungal prophylaxis for neonates are recommended


Therapeutic Hypothermia: Drug Therapy considerations
0180-0000-16-201-L01-P
10:35:00 AM - 10:55:00 AM
Marquis Ballroom B

Shabnam Gaskari, PharmD
Pharmacist
Lucile Packard Children's Hospital Stanford
Palo Atlo, California

At the end of this session, participants will be able to:

1.       Demonstrate knowledge for Antiepileptic Drugs in Neonate

2.      Demonstrate knowledge for Sedation and Analgesia in Neonate

3.      Learn about Effect of Therapeutic Hypothermia on Drug Metabolism


You Raise Me Up:  Vasopressin for Refractory Neonatal Hypotension
0180-0000-16-202-L01-P
11:00:00 AM - 11:20:00 AM
Marquis Ballroom B

Emily Rodman, PharmD
Clinical Pharmacy Specialist- NICU/Women's Services
Texas Children's Hospital
Houston, Texas

At the end of this session, participants will be able to:

1.       Understand the etiology and treatment options of neonatal hypotension

2.       Review the literature to support the use of vasopressin for refractory neonatal hypotension

3.       Understand the potential adverse effects of vasopressin in neonates


Tales from the Crib: Medication Event Prevention and Error Reduction in the NICU
0180-0000-16-203-L05-P
11:30:00 AM - 12:30:00 PM
Marquis Ballroom B

Kristin Klein, PharmD, FPPAG
Clinical Associate Professor
University of Michigan
Ann Arbor, MI

James Newman
Human Performance Tools, LLC
www.HumanPerformanceTools.com
Jewett City, CT

At the end of this session, participants will be able to:

1.       Describe the error traps that may contribute to medication prescribing, dispensing, or administering errors in the NICU.

2.       Identify the critical steps in the medication use process where extra diligence may be required to prevent latent or active medication errors.

3.       Weigh the advantages and disadvantages between voluntary medication error reporting processes, and mandatory reporting processes. 

4.       Describe at least 4 ways medication errors can be prevented in the NICU.

5.       Propose a process for implementing a just medication error reporting culture at your institution.


Where do you draw the line?: Central Line Management in Neonates and Infants
0180-0000-16-204-L01-P
2:00:00 PM - 2:30:00 PM
M103-M105

Kathy Pham, PharmD
NICU Clinical Specialist; Residency Program Director
Children's National
Washington, District of Columbia

At the end of this session, participants will be able to:

1.       Evaluate the utility of heparin-containing products for maintaining line patency in neonates

2.      Analyze and interpret existing evidence of antifungal prophylaxis in neonates with central venous access

3.      Develop standardized continuous infusion practices based on CDC recommendations, nursing considerations and pharmacy workflow optimization


Neonates, Bugs and Lines: A look at preventing sepsis post-catheter removal
0180-0000-16-205-L01-P
2:00:00 PM - 2:30:00 PM
Marquis Ballroom B

Sarah Tierney, Pharm.D
Clinical Pharmacy Specialist
University of Iowa Children's Hospital
Iowa City, Iowa

At the end of this session, participants will be able to:

1.       Identify patients at highest risk for post-catheter removal clinical sepsis

2.      Compare and contrast prevention methods for post-catheter removal clinical sepsis

3.      Develop guidelines for decreasing incidence of post-catheter removal clinical sepsis


Controversies in Neonatal Drug Therapy
0180-0000-16-206-L01-P
2:40:00 PM - 4:45:00 PM
M103-M105

Sherry Luedtke, PharmD, FPPAG
Associate Professor
Texas Tech HSC SOP
Amarillo, TX

Christopher McPherson, PharmD
Clinical Pharmacist
Brigham and Women's Hospital
Boston, MA

Peter Gal, PharmD, FPPA
Associate Dean
High Point University School of Pharmacy
High Point, North Carolina

At the end of this session, participants will be able to:

1.    Distinguish the role of emerging therapies for PDA in current practice

2.   Select the optimal intervention for infants with NAS

3.   Identify the advantages and disadvantages of different corticosteroids for the prevention of BPD and Analyze the risks and benefits of early prophylactic caffeine therapy


 


Probiotics to Prevent NEC: Panacea or Placebo?
 
2:40:00 PM - 3:40:00 PM
Marquis Ballroom B

Jennifer Pham, PharmD, BCPS, BCPPS
Clinical Assistant Professor/Neonatal Clinical Pharmacy Specialist
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Kirsten Ohler, Pharm.D., BCPS, BCPPS
Clinical Assistant Professor / Neonatal Clinical Pharmacy Specialist
University of Illinois at Chicago, College of Pharmacy
Chicago, IL

At the end of this session, participants will be able to:

1.       Describe the incidence and risk factors for necrotizing enterocolitis.

2.       Discuss the evidence supporting the efficacy of probiotics for the prevention of necrotizing enterocolitis.

3.       Discuss the safety concerns surrounding the use of probiotics in neonates.


Iatrogenic Withdrawal in the Neonate
0180-0000-16-208-L01-P
3:45:00 PM - 4:45:00 PM
Marquis Ballroom B

Emily Polischuk, Pharm.D.
Clinical Staff Pharmacist
Women and Children's Hospital of Buffalo
Buffalo, New York

At the end of this session, participants will be able to:

1.       Compare and contrast the cause, diagnosis, and symptoms of neonatal abstinence syndrome (NAS) and neonatal iatrogenic withdrawal

2.      Given length and total dose of opioid exposure, identify neonates at a high risk for developing iatrogenic withdrawal

3.      Based on limited literature available, recommend a pharmacologic agent, initial dosing, and weaning schedule for the treatment of iatrogenic withdrawal


Keynote Address:
Parenting a Medically Fragile Child

0180-0000-16-209-L04-P
5:00:00 PM - 6:00:00 PM
Marquis Ballroom B

Melissa Waide, MSN, CPNP
Renal Transplant Coordinator
Children's Hospital of the King's Daughter
Norfolk, Virginia

At the end of this session, participants will be able to:

1.       Identify the limitations in the home environment that may be sub-optimal for medication administration

2.       Recognize the need for behavioral medication management in children with chronic illness

3.       Acnowledge factors that impact quality of life (I.e., pill burden, side effect management, and medication cost)

4.       Proactively demonstrate creative ways to help these families make their routines simpler and safe

 

Thursday, April 28, 2016 | NICU Sessions

[Student Award Finalist Platform] HSV PCR testing and acyclovir use in children: a five year review
8:00:00 AM - 9:00:00 AM
M103-M105

Allison Stefanski, PharmD Candidate
University of Rhode Island


[Student Award Finalist Platform] The development of an evidence based, standardized formulary for the pediatric extemporaneous oral liquid compounds of the Gateway Pediatric Pharmacy Group
8:00:00 AM - 9:00:00 AM
M103-M105

Kyle Dillon, PharmD Candidate
South Ilinois University Edwardsville


[Student Award Finalist Platform] Prevalence of Adverse Effects Among children Receiving Peg-Asparaginase or Ervinia Asparaginase Based on Intravenous versus Intramuscular Routes of Administration
8:00:00 AM - 9:00:00 AM
M103-M105

Megan Corsi, PharmD Candidate
Roseman University
Note: Ms. Corsi will be presenting her Platform during the Scientific Platform Presentations on Friday, April 29, 2016


[Student Award Finalist Platform] Evaluation of Common Medication and Risk of Necrotizing Enterocolitis in Very Low Birth Weight Infants
8:00:00 AM - 9:00:00 AM
M103-M105

Katelyn Bull, PharmD Candidate
South Carolina College of Pharmacy
Note: Ms. Bull will be presenting her Platform during the Scientific Platform Presentations on Friday, April 29, 2016


Cutting Edge Neonatal Anti-Infective Pharmacokinetics
0180-0000-16-210-L01-P
8:00:00 AM - 8:20:00 AM
Marquis Ballroom B

Jeffrey Cies, PharmD, MPH, BCPS-AQ ID
Pharmacy Clinical Coordinator, Critical Care and Infectious Diseases Clinical Pharmacist
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania

At the end of this session, participants will be able to:

1.       Review current ampicillin dosing recommendations pharmacokinetics (PK)

2.      Discuss ampicillin PK changes in the following settings: 
   a. Hypothermia       
  
 b. Extra-corporeal life support (ECLS)


I can see clearly now: Intravitreal Bevacizumab for Retinopathy of Prematurity (ROP)
0180-0000-16-211-L01-P
8:20:00 AM - 8:40:00 AM
Marquis Ballroom B

Kimberly Dinh, PharmD
Clinical Pharmacy Specialist
Texas Children's Hospital
Houston, Texas

At the end of this session, participants will be able to:

1.       Understand the pathophysiology of ROP

2.      Review the literature for the use of intravitreal bevacizumab for the treatment of ROP

3.      Identify a strategy to safely dispense and administer small doses of intravitreal bevacizumab at the bedside


Gabapentin Use in the NICU
0180-0000-16-212-L01-P
8:40:00 AM - 9:00:00 AM
Marquis Ballroom B

Kay Kyllonen, PharmD, FPPAG
NICU Specialist
Cleveland Clinic Children’s Hospital
Cleveland, Oh-io

At the end of this session, participants will be able to:

1.       TBD


Anticoagulation in the NICU
0180-0000-16-213-L01-P
9:05:00 AM - 10:05:00 AM
Marquis Ballroom B

Dave Procaccini, BCPS AQ-Cardiology, CACP
Clinical Pharmacy Specialist - Pediatric Intensive Care, Cardiology, and Anticoagulation
The Johns Hopkins Hospital
Baltimore, Maryland

At the end of this session, participants will be able to:

1.       TBD


Pharmacotherapy Inertia in the NICU: Continuing to Use Agents That We Have Always Used
0180-0000-16-214-L01-P
10:15:00 AM - 11:15:00 AM
Marquis Ballroom B

Bob John, Pharm.D., BCPS
NICU Clinical Pharmacy Specialist
The Children's Hospital at Saint Francis
Tulsa, Oklahoma

Jamie Miller, Pharm.D., BCPS, BCPPS
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

At the end of this session, participants will be able to:

1.     Describe the current role of probiotics, phenobarbital, and vitamin A use in the NICU.

2.    Explain the data for safety and efficacy for use of phenobaribital and probiotics in various neonatal disease states

3.    Evaluate the data for and against the use of Vitamin A for BPD prophylaxis  4) Identify barriers to change NICU clinicians may face when using newer therapies and removing established therapies.


Managing pulmonary hypertension after iNo fails
0180-0000-16-215-L01-P
11:20:00 AM - 12:20:00 PM
M103-M105

Alex Oschman, PharmD
Intensive Care Nursery Clinical Pharmacy Specialist
Children's Mercy Hospital
Kansas City, Missouri

At the end of this session, participants will be able to:

1.       TBD


Go with the Flow: A Pharmacists' Guide to Medications in ECMO Patients
0180-0000-16-216-L01-P
11:20:00 AM - 12:20:00 PM
Marquis Ballroom B

Emily Rodman, PharmD
Texas Children’s Hospital
Clinical Pharmacy Specialist- NICU/Labor & Delivery
Houston, Texas

At the end of this session, participants will be able to:

1.       Review common medications administered to ECMO patients in the NICU

2.      Discuss pharmacokinetic changes that occur in ECMO patients

3.      Identify commonly used medications that can adhere to ECMO circuits


[Student Session] Bugs and Drugs: Common Infections in Pediatrics
2:00:00 PM - 2:30:00 PM
M103-M105

Richard Haftmann, PharmD
Resident, University of Arizona
Tucson, Arizona

Ashley Repholz, PharmD
Resident, University of Arizona
Tucson, Arizona


[Student Session] The Role of Pediatric Pharmacist in Pediatric Emergency Department: Once Center's Experience
2:30:00 PM - 3:00:00 PM
M103-M105

Peter Aiello, PharmD
Resident, Upstate Medical University
Baldwinsville, New York


[Student Session] Medication Safety: Pediatric Considerations
3:00:00 PM - 3:30:00 PM
M103-M105

Sarah Shields, PharmD
Resident
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio


[Student Session] From Match Day to Midyear: Navigating the Journey from Student to Resident
3:30:00 PM - 4:00:00 PM
M103-M105

Courtney Chandler, PharmD
Resident
Children’s Medical Center
Dallas, Texas


Resident Project Presentations
4:15:00 PM – 6:30:00 PM
Marquis Ballroom B


Resident Project Presentations
4:15:00 PM – 6:30:00 PM
M102


Resident Project Presentations
4:15:00 PM – 6:30:00 PM
M103-M105


Resident Project Presentations
4:15:00 PM – 6:30:00 PM
M106


Resident Project Presentations
4:15:00 PM – 6:30:00 PM
M302

 

 

Friday, April 29, 2016 | NICU and Nutrition/GI BRIDGE DAY

Sumner J. Yaffe Lifetime Achievment Award in Pediatric Pharmacology and Therapeutics Lecture
0180-0000-16-217-L04-P
8:00:00 AM - 9:00:00 AM
Marquis Ballroom B

Stanley Szefler, MD
Director of Pediatric Asthma Research Program
Children's Hospital of Colorado
Aurora, Colorado


Chiesi Best Practice Award Presentation
A collaborative practice agreement for pharmacist triage of medication related calls following patient discharge from a pediatric emergency department

0180-0000-16-218-L01-P
9:05:00 AM - 9:20:00 AM
Marquis Ballroom B

Ean Miller, PharmD, BCPPS, BLS, ACLS, PALS
Pediatric Clinical Specialist, Emergency Department
Cook Children's Medical Center
Fort Worth, Texas


Scholarship in Teaching Award Presentation
Curricular preferences and subsequent employment choices of pediatric degree option graduates

0180-0000-16-219-L01-P
9:20:00 AM - 9:35:00 AM
Marquis Ballroom B

Brooke Gildon, PharmD
presented by Peter Johnson, PharmD, FPPAG

Associate Professor
University of Oklahoma
Oklahoma City, Oklahoma  


Scientific Platform Presentation
Efficacy and Safety of Intravenous Magnesium Use for Status Ashmaticus in the Pediatric Intensive Care Unit

0180-0000-16-220-L01-P
9:35:00 AM - 9:50:00 AM
Marquis Ballroom B

Grace Lee, PharmD
Children's Hospital of Orange County
Orange, California


Scientific Platform Presentation
Prevalence of Adverse Effects Among children Receiving Peg-Asparaginase or Ervinia Asparaginase Based on Intravenous versus Intramuscular Routes of Administration

0180-0000-16-221-L01-P
9:50:00 AM - 10:05:00 AM
Marquis Ballroom B

Megan Corsi
PharmD Candidate
Roseman University
Salt Lake City, Utah


Scientific Platform Presentation
Evaluation of Common Medication and Risk of Necrotizing Enterocolitis in Very Low Birth Weight Infants

0180-0000-16-222-L01-P
10:05:00 AM - 10:20:00 AM
Marquis Ballroom B

Katelyn Bull
PharmD Candidate

South Carolina College of Pharmacy
Columbia, South Carolina


Scientific Poster Session
?10:20:00 AM - 11:40:00 AM
Marquis C

 


Fellows in the Pediatric Pharmacy Advocacy Group (FPPAG) Induction Ceremony
11:40:00 AM - 12:00:00 PM
Marquis B


Town Hall Lunch
12:00:00 PM - 1:00:00 PM
Marquis B


BPS and BCPPS Update
1:00:00 PM - 1:30:00 PM
Marquis B

William Ellis, MS, RPh
Executive Director, Board of Pharmacy Specialties
Washington, DC


Richard A. Helms Award of Excellence in Pediatric Pharmacy Practice Lecture
0180-0000-16-223-L04-P
1:35:00 PM - 2:35:00 PM
Marquis Ballroom B

Michael Christensen, PharmD
Professor, Clinical Pharmacy
University of Tennesee Health Science Center
Memphis, Tennessee


[Student Session] Applying to Pharmacy Residencies:Writing a Letter of Intent
2:40:00 PM - 3:10:00 PM
M103-M105

Gwen Nance, PharmD
Resident
Children’s of Alabama
Birmingham, Alabama


[Student Session] Applying to Pharmacy Residencies:Writing a Letter of Intent
2:40:00 PM - 3:10:00 PM
M103-M105

Jessica Hoover, PharmD
Resident
Children’s Memorial Hermann Hospital
Houston, Texas


[Student Session] Yellow Brick Road of Residency Research
3:10:00 PM - 3:40:00 PM
M103-M105

Kyle Franco, PharmD
Resident
UF Health Shands Hospital
Gainsville, Florida


New Practitioners Ice Cream Social
3:40:00 PM – 4:40:00 PM
Skyline South


PPAG Reception of Gratitude and Thanks
All Committee and SIG Chairs and Members invited
6:00:00 PM – 7:00:00 PM
Skyline South

 

Saturday, April 30, 2016  | Nutrition/GI Sessions

Drug Induced Liver Disease
0180-0000-16-224-L01-P
8:00:00 AM - 8:20:00 AM
Marquis Ballroom B

Tracy Sandritter, Pharm.D., BCPPS
Clinical Specialist
Children's Mercy Hospital
Kansas City, Missouri

At the end of this session, participants will be able to:

1.                       1.       Name the most common drug associated with liver disease in children

2.       Recognize the different types of drug induced liver disease

3.       Understand the pathology of drug induced liver disease


TPN starter implementation in Neonatal Intensive Care Unit
0180-0000-16-225-L01-P
8:20:00 AM - 8:40:00 AM
Marquis Ballroom B

Therese Saad, Pharm D, BCPS
Clinical Pharmacist Pediatric Team Leader
American University of Beirut Medical Center
Beirut, Lebanon

At the end of this session, participants will be able to:

1.       Compare Late and Early TPN in preterm infants

2.      Define the importance of early nutrition support


If you only knew the power of the darkside:  light protecting TPN and fat emulsions
0180-0000-16-226-L01-P
8:40:00 AM - 9:00:00 AM
Marquis Ballroom B

Kimberly Dinh, PharmD
Texas Children's Hospital
Houston, Texas

At the end of this session, participants will be able to:

1.       Review the pathophysiology of oxidant stress and impact on outcomes in premature infants.

2.      Review the literature that supports the photoprotection of TPN and fat emulsions

3.      Identify operational concerns with implementing a process to cover TPN from light


Student Chapter Poster Session
9:00:00 AM - 11:00:00 AM
TBA


The Long and the Short of Short Bowel Syndrome
0180-0000-16-227-L01-P
9:05:00 AM - 10:05:00 AM
Marquis Ballroom B

Pooja Shah, Pharm.D., BCPPS
Clinical Assistant Professor
Ernest Mario School of Pharmacy at Rutgers University
Piscataway, New Jersey

Anita Siu, Pharm.D., BCPPS
Clinical Associate Professor
Rutgers University
Piscataway, New Jersey

At the end of this session, participants will be able to:

1.    Recognize challenges in the initial and long term management of neonate with short bowel syndrome (SBS) including nutritional management, liver disease, and intestinal motility.

2.   Evaluate the risks and benefits of the therapeutic agents used for the complications associated with neonatal SBS while highlighting role of pharmacists in SBS management.

3.   Formulate the most appropriate pharmacologic treatment of choice or alternatives for neonate with SBS given a patient case.


Faced with Foregoing Fats? Alternate Lipid Therapies.
0180-0000-16-228-L01-P
10:35:00 AM - 11:05:00 AM
Marquis Ballroom B

Jennifer Placencia, Pharm.D.
Clinical Pharmacy Specialist
Texas Children's Hospital
Houston, Texas

At the end of this session, participants will be able to:

1.       Recall the role lipids play in Parenteral Nutrition-Associated Liver Disease (PNALD)

2.       Identify the different formulations of alternate lipid emulsion therapies available in the management of PNALD.

3.       Evaluate alternate lipid emulsion therapy in the management of  PNALD


The link between PN liver injury and fat - is it the dose or type of oil?
0180-0000-16-229-L01-P
10:35:00 AM - 11:35:00 AM
M103-M105

Kathleen Gura, Pharm.D., BCNSP, FASHP, FPPAG, FASPEN
Manager, Clinical Research
Boston Children's Hospital
Boston, MA

At the end of this session, participants will be able to:

1.       Understand how different oil sources may predispose patients to PNALD

2.      Understand the role of phytosterols and alpha tocopherol in lipid emulsions

3.      Describe one lipid restriction appropach in treating children with PNALD


Comprehensive Neonatal Cardiac Nutrition: Carnitine Supp for the Neonatal Heart and Selenium for the Soul
0180-0000-16-233-L01-P
11:05:00 AM - 11:35:00 AM
Marquis Ballroom B

Brian Brown, Pharm.D., BCPS, BCPPS
Clincal Pharmacist
All Children's Hospital Johns Hopkins Medicine
Saint Petersburg, Florida

Bernard Lee, Pharm.D., BCPS, BCPPS
Clinical Pharmacist
All Children's Hospital Johns Hopkins Medicine
St. Petersburg, Florida

At the end of this session, participants will be able to:

1.       Explore the rationale behind early neonatal nutrition interventions.

2.      Evaluate the utility of current nutritional support measures in neonates with cardiac lesions

3.      Discuss novel strategies of nutrition support in neonates at various stages of cardiac lesion management


Provision of trace elements in the neonate - What the baby really wants
0180-0000-16-231-L01-P
1:00:00 PM - 1:30:00 PM
Marquis Ballroom B

M.Petrea Cober, PharmD, BCNSP
Clinical Coordinator - Neonatal Intensive Care Unit/Associate Professor of Pharmacy Practice
Akron Children's Hospital/Northeast Ohio Medical University, College of Pharmacy
Akron/Rootstown, OH

At the end of this session, participants will be able to:

1.       Identify the current ASPEN recommendation for trace element provisions in the neonate

2.      Describe the difficulty in complying with ASPEN recommendations given currently available products and the impact of drug shortages

3.      Discuss specific recommendations based on various patient populations in the neonatal intensive care unit


Liver Transplant
0180-0000-16-232-L01-P
1:00:00 PM - 2:05:00 PM
M103-M105

Rochelle Liverman, Pharm.D.
Pediatric Transplant Pharmacist Specialist
Children's Healthcare of Atlanta
Atlanta, Georiga

At the end of this session, participants will be able to:

1.       Identify the most common indications for pediatric liver transplantation

2.      Characterize the needs of transplant recipients pre and post transplant

3.      Describe the role of the transplant pharmacist


Appetite Stimulants in Children
0180-0000-16-230-L01-P
1:35:00 PM - 2:05:00 PM
Marquis Ballroom B

Tracy Hagemann, PharmD
Professor and Associate Dean
University of Tennessee College of Pharmacy
Nashville, TN

At the end of this session, participants will be able to:

1.       Describe the suspected causes for appetite suppression and cachexia in children

2.      Recommend pharmacotherapy for stimulation of appetite in pediatric patients.

3.      Recognize the role that immunomodulary agents may play in pharmacotherapy for appetite stimulation in pediatric patients.


Keynote Address: KiDS Georgia- ICAN
0180-0000-16-234-L04-P
2:10:00 PM - 3:10:00 PM
Marquis Ballroom B


Resident Project Presentations
3:20:00 PM – 5:30:00 PM
Marquis Ballroom B


Resident Project Presentations
3:20:00 PM – 5:30:00 PM
M102


Resident Project Presentations
3:20:00 PM – 5:30:00 PM
M103-M105


Resident Project Presentations
3:20:00 PM – 5:30:00 PM
M106


Resident Project Presentations
3:20:00 PM – 5:30:00 PM
M302

 

Sunday May 1, 2016 | Nutrition/GI Sessions

Exclusive Enteral Nutrition in Crohn's: Step Aside Steroids
0180-0000-16-235-L01-P
8:00:00 AM - 8:15:00 AM
Marquis Ballroom B

Melissa Gervase, Pharm.D., BCPPS, AE-C
Pediatric Clinical Pharmacy Specialist
Cook Children's Medical Center
Fort Worth, TX

At the end of this session, participants will be able to:

1.       Recall basic pathophysiology of Crohn’s Disease

2.      Explain how nutritional status is altered by Crohn’s disease

3.      Examine the role of exclusive enteral nutrition in Crohn’s

 


Updates in IBS
0180-0000-16-236-L01-P
8:20:00 AM - 8:35:00 AM
Marquis Ballroom B

Christina Cox, PharmD
Assistant Professor
South Carolina College of Pharmacy
Columbia, South Carolina

At the end of this session, participants will be able to:

1.       TBD


Total Pancreatectomy and Islet Auto-Transplantation
0180-0000-16-237-L01-P
8:40:00 AM - 9:40:00 AM
Marquis Ballroom B

Kristina Nelson, PharmD
Pediatric Clinical Pharmacist
University of Minnesota Masonic Children's Hospital
Minneapolis, MN

At the end of this session, participants will be able to:

1.       Describe challenges in pain management following TPIAT and discuss therapy options for post-operative management

2.      Develop a plan for the management of exogenous pancreatic exocrine and endocrine function following TPIAT

3.      Describe typical post-operative issues and the principles of management

 


The Ever Evolving Practice of Pediatric Parenteral Nutrition: Contemporary Products, Current Topics, Clinical Conundrums, and Continuing Controversies
0180-0000-16-238-L01-P
9:50:00 AM - 11:55:00 AM
M103-M105

Catherine M. Crill, PharmD, FCCP, BCPS, BCNSP
Associate Professor of Clinical Pharmacy and Pediatrics
The University of Tennessee Health Science Center
Memphis, TN

Oscar R. Herrera, Pharm.D., BCNSP
Clinical Pharmacist / Assistant Professor
UTHSC College of Pharmacy
Memphis, Tennessee

At the end of this session, participants will be able to:

1.     Discuss the application of novel lipid, new nutrient and pharmacological, and imported products in the provision of nutrition support to pediatric patients.

2.    Design safe and effective parenteral nutrition regimens for pediatric patients taking into account evidence on current topics (PN photoprotection, nutrient deficiencies/toxicities in the age of product shortages, PN Safety Consensus and sterile compoundin

3.   Evaluate the evidence with respect to clinical conundrums (lipid administration and repackaging, ethanol lock therapy) and controversies (nutrient intake and treatment in PNALD, PN support in critically ill patients) in pediatric nutrition practice.


Constipation: Don't Poo-Poo It, Clean it Out
 0180-0000-16-239-L01-P
9:50:00 AM - 10:50:00 AM
Marquis Ballroom B

Allison B. Lardieri, PharmD, BCPPS
Assistant Professor
University of Maryland School of Pharmacy
Baltimore, MD

Jill A. Morgan, PharmD, BCPS, BCPPS
Associate Professor
University of Maryland School of Pharmacy
Baltimore, MD

At the end of this session, participants will be able to:

1.       Formulate a list of pertinent questions to gather patient histories related to constipation.

2.      Given a patient case, develop an appropriate disimpaction and maintenance treatment plan.

3.      Develop patient education and monitoring plans for patients from infants to adolescents.


Issues in Providing Care to Pediatric and Neonatal Patients Receiving Parenteral Nutrition
0180-0000-16-240-L01-P
10:55:00 AM - 11:55:00 AM
Marquis Ballroom B

Steve Plogsted, PharmD
Nationwide Children's Hospital
Columbus, Ohio

At the end of this session, participants will be able to:

1.       Demonstrate pediatric parenteral nutrition order writing and management skills

2.      Discuss appropriate markers for monitoring nutritional adequacy

3.      Discuss the need for early parenteral nutrition in the neonate


Antimicrobial stewardship practices in abdominal infections
0180-0000-16-241-L01-P
12:05:00 PM - 1:05:00 PM
Marquis Ballroom B

Chad Knoderer, PharmD, FPPAG
Associate Professor of Pharmacy Practice
Butler University College of Pharmacy and Health Sciences
Indianapolis, IN

Kristen Nichols, PharmD, BCPPS, BCPS (AQ-ID)
Assistant Professor, Pharmacy Practice
Butler University College of Pharmacy and Health Sciences
Indianapolis, IN

At the end of this session, participants will be able to:

1.       Identify core strategies for effective antimicrobial stewardship in patients with abdominal infections

2.      Assess stewardship efforts using institutional data

3.      Engage practitioners in antimicrobial stewardship efforts

 

 

 

Calendar of Events

Upcoming Webinars

On-Demand Programs

 

Fall Conference